Acquirer · Corporate
Eli Lilly
4$13.68bn$2.88bn0
Photo: Paul Sableman / Wikimedia Commons, CC BY 2.0Eli Lilly agrees to buy Merida Biosciences for up to $2.875 billion
Lilly is paying up to $2.875 billion in cash for a company that announced its $121 million Series A only 16 months earlier. Merida's lead drug, in Phase 1, is designed to remove the antibodies that cause Graves' disease rather than suppress the whole immune system.
$2.88bn$121mSeries ACorporate
Latest in Eli LillyBothell · Healthtech & bioEli Lilly agrees to buy shingles vaccine developer Curevo for up to $1.5 billion
New York · Healthtech & bioEli Lilly agrees to buy Ajax Therapeutics for up to $2.3 billion
Boston · Healthtech & bioEli Lilly to acquire Kelonia Therapeutics for up to $7 billion in cash
New York · Healthtech & bioEli Lilly agrees to buy Ajax Therapeutics for up to $2.3 billionBoston · Healthtech & bioEli Lilly to acquire Kelonia Therapeutics for up to $7 billion in cash